uniQure Reports Q2 2025 Financial Results with Revenue Decline and Improved Net Loss

uniQure N.V. reported its financial results for the second quarter of 2025, revealing a total revenue of $5.3 million, a significant decrease from $11.1 million in the same period last year. The decline was primarily attributed to the absence of contract manufacturing and collaboration revenues, which were $2.1 million and $7.1 million, respectively, in the prior year. The company’s license revenues, however, increased to $5.3 million from $1.9 million, reflecting growth in royalties from its gene therapy product, HEMGENIX®. For the first half of 2025, total revenues amounted to $6.8 million, down from $19.6 million in the first half of 2024.

The company reported a net loss of $37.7 million for the second quarter, an improvement compared to a net loss of $56.3 million in the same quarter of 2024. For the first six months of 2025, the net loss was $81.4 million, down from $121.9 million in the same period last year. The reduction in losses was attributed to lower operating expenses, which decreased to $49.5 million in the second quarter from $56.9 million in the prior year, driven by reduced research and development costs and selling, general, and administrative expenses.

In terms of strategic developments, uniQure has made significant progress with its lead product candidate, AMT-130, for Huntington’s disease. The FDA granted Breakthrough Therapy designation for AMT-130 in April 2025, and the company is preparing for a potential Biologics License Application (BLA) submission. Additionally, the company appointed Kylie O’Keefe as Chief Customer and Strategy Officer in June 2025, aiming to enhance its commercial and medical affairs.

Operationally, uniQure's total assets increased to $584.9 million as of June 30, 2025, up from $556.5 million at the end of 2024. The company’s cash and cash equivalents rose to $253.8 million, compared to $158.9 million at the end of the previous fiscal year. The increase in cash was bolstered by a follow-on public offering in January 2025, which generated net proceeds of $70.1 million. The company anticipates that its existing cash resources will fund operations into the second half of 2027, although it may require additional financing to support the commercialization of AMT-130 and other product candidates.

Looking ahead, uniQure remains focused on advancing its gene therapy pipeline, which includes AMT-260 for temporal lobe epilepsy, AMT-191 for Fabry disease, and AMT-162 for amyotrophic lateral sclerosis. The company acknowledges the inherent risks in drug development and the need for ongoing funding to support its research and development efforts. As it navigates these challenges, uniQure aims to leverage its recent regulatory designations and strategic initiatives to enhance its market position and drive future growth.